u/ahmed_rasmussen

The effect on gastric emptying is most pronounced early and attenuates with continued dosing, which is the mechanism behind the "it settles at a stable dose" pattern the whole board reports.

That is an employer plan process, and the provincial route is different in both form and timeline.

ask the pharmacy what the cash price is, it varies

Right, and the hair thing is worth repeating: it tracks the rate of loss rather than the compound, and it stops.

Small fix — those two prices are for different pack sizes, which accounts for most of the gap.

Small fix — the shedding follows the rate of weight loss, not the compound, and it is temporary.

The PDF creation date being later than the analysis date is usually a re-issue or a re-export. It is worth one question and it is not evidence of anything on its own.

area% is not mass%, and the difference is the whole game

Same pattern here. It settled at a stable dose without me doing anything clever.

Yes — system suitability first. Without it the number is an assertion about the instrument, not the sample.

This. Area percent answers "what fraction of what the detector saw was the peak I wanted", and people read it as "how much peptide is in the vial".

Carryover from a previous high-concentration injection looks exactly like a small impurity.

Adding one practical thing — run the blank. It answers this before anyone has to argue about it.

Asked in my own language at a local pharmacy and got a clearer answer in five minutes than a fortnight of forum reading.

axis labels or the trace is decoration

Agreed — authorisation is European, reimbursement is national, and almost every confused thread here misses that split.

batch number, date of analysis, method, individual impurities — that is the minimum set

Started reconstituting everything to a round concentration and the six-in-the-morning error rate went to zero.

Nothing here is medical or legal advice. The pharmacist and the prescriber are the people who can act, and both are faster than a forum.

That symptom is not the one being described upthread. Two different things with similar names and the answers are not interchangeable.

Mine settled at week 18 and has not come back since, across two more steps.

Wrote the date on the vial as well as the concentration after losing track of which one was opened first.

LC-MS gives you identity; UV purity gives you a relative quantity. A document with the first and not the second, or the reverse, is answering half the question.

Push back: a longer run is not automatically better resolution. You are trading peak width for time and the ratio is what matters.

Small fix — 214nm, not 210. It matters for the comparison you are making with the other run.

Nothing in this thread is medical advice, including this comment. I am describing a mechanism, not telling anybody what to do about their own week.

A shoulder that does not baseline-resolve cannot be quantified honestly. You can report it as an unresolved shoulder, which is useful information, or you can develop the method until it resolves.

Agreed, and it is why FGP printing the column and gradient on the certificate is genuinely useful rather than decorative.

axis labels included, always

Aim the stream down the wall of the vial rather than into the cake. Reconstitution is a solubility problem, not a mixing problem, and mechanical shear does nothing helpful.

Same method at both labs, or two different gradients?

Can you post the trace with the axes labelled?

area percent is relative to what the detector saw and nothing else

Retention time shifted 0.4 minutes and I assumed the worst. It was the column temperature.

How many mg in the vial and how many mL are you adding?

I would be careful here. "Everyone gets this" is not true, and it makes the people who get something unusual assume they are fine when they should be asking.

Yes, and the dead-space point is worth repeating: it is small, it is real, and it is the same for every draw.

Which day of the week relative to the shot does it hit?